01.
1st line treatment of Glioblastoma
Phase II clinical trials are in progress in the US for the 1st line glioblastoma treatment with ITI-1---(pp65-LAMP DC) therapy
UNITE platform is a powerful next-generation vaccine platform technology that targets specific antigens to lysosomes to enhance antigen presentation ability and enhances cytotoxic T cell function.
The anticancer drug under development using the UNITE platform technology from Immunomic Therapeutics is an immune anticancer drug that enhances the immune system of cancer patients by mounting cancer-specific antigens on immune cells with high efficiency.
Glioblastoma is a primary tumor originating from the brain-spinal tissue or the membrane that surrounds it. It is a tumor originated from the glioma cells (Neuroglia Cells) that are normally abundant in brain tissue.
Glioblastoma is grade 4 in astrocytoma and is the most malignant among astrocytoma and histologically, necrosis is added to anaplastic astrocytoma.
This tumor is the most common primary brain tumor, accounting for 1/2 of glioma and 15% of pediatric glioma, and rarely occurs in the cerebellum.
The 2000 WHO taxonomy includes glioblastomas, including giant cell glioblastoma and gliosarcoma.
* source: National Information Cancer Center
Program | Therapeutic Area | Indication | Target / Modality | Stage of Development | Lead Developing Entity | |||||||
Discovery | Pre-clinical | Phase 1 | Phase 2 | |||||||||
ITI-1000 | Oncology | GBM | DC-based pp65 CMV |
|
Immunomic | |||||||
ITI-1001 | Oncology | GBM | pDNA pp65.gB, IE1:CMV |
|
Immunomic | |||||||
ITI-2000 | Oncology | HPV+ Tumors | HPV E6/E7 |
|
Immunomic | |||||||
ITI-4000 | Oncology | NPC / Gastric | Epstein-Barr Virus |
|
Immunomic | |||||||
ITI-6000 | Oncology | HCC | HBV ag + Others |
|
Immunomic | |||||||
ITI-7000 | Oncology | Bladder | HERS+NY=ESO-1 |
|
Immunomic | |||||||
ITI-3000 | Oncology | Markel Cell Carcinoma | Polyoma pDNA |
|
Hutch/UW | |||||||
ITI-5000 | Oncology | Neoantigen vaccination | PCV pDNA |
|
Eplvax Oncology | |||||||
ITI-AB1 | Oncology (biologic - MAB) | Checkpoint Inhibitor | HVEM |
|
Immunomic | |||||||
ASP-JRCv2.0 | Allezy | Japanese Ped Cedar | pDNA |
|
Astellas | |||||||
ASP-0892 | Allezy | Peanut | pDNA |
|
Astellas | |||||||
ASP-2390 | Allezy | HDM + other Allergens | pDNA |
|
Astellas | |||||||
Animal Health | All | All | pDNA |
|
Zenoaq |
Phase II clinical trials are in progress in the US for the 1st line glioblastoma treatment with ITI-1---(pp65-LAMP DC) therapy